Dishman Carbogen Amcis Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹507 Cr −22.3% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
DC

Dishman Carbogen Amcis Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Dishman Carbogen Amcis Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹851Cr
+18.9% YoY
+18.2% QoQ
Net profit
₹22Cr
−48.8% YoY
Turned profitable QoQ
Margin
19%
−2 pp YoY
+3 pp QoQ

What the Q4 FY26 call signalled

2 of 5 strong

RevenueModerate growth
MarginMargins steady
CapexNo capex planned
FundraiseFundraise planned
Order bookOrder book rising
Price₹174
Market cap₹3.0K Cr
P/E164.8

The short version

The company targets a consolidated revenue CAGR of approximately 15% over the next 2-3 years, higher than the 10-12% growth achieved previously. Revenue CAGR expected at ~15% over the next 3 years, higher than previous years (Page 28).

From Dishman Carbogen Amcis Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Moderate growth
  • The company targets a consolidated revenue CAGR of approximately 15% over the next 2-3 years, higher than the 10-12% growth achieved previously. (Page 28)
  • India business aims to grow significantly, targeting INR 500 crores revenue by FY28, benefiting from tech transfers and multiple projects in the pipeline. (Pages 12, 18, 23)
  • Stand-alone India revenue expected to increase in FY27 versus FY26, with potential to reach or exceed FY25 levels (~INR 400 crores) and grow further in FY28. (Page 19)
  • CDMO segment to maintain approximately 85% share of revenues and grow steadily; marketable molecules about 15%. (Page 16)
  • Margins in both CDMO and marketable molecule segments expected to improve, targeting 25% EBITDA margin by FY28. (Page 15)

2 more points from Dishman Carbogen Amcis Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Dishman Carbogen Amcis Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

No capex planned
  • No major CapEx plans currently, except for co-investment with a Japanese innovator, where 100% of CapEx financing is by the partner (Page 18).
  • Ongoing maintenance CapEx will continue group-wide.
  • Investments planned in digital transformation, including SAP implementation across the group, lab management software, and exploring AI for process efficiencies (Page 18).
  • The recent Swiss manufacturing line went live in Q4 FY25; no significant new fixed assets planned beyond current capacity (Page 9).
  • Some CapEx may be required in the future, but not planned currently; financing sources considered cheap and flexible (Page 26).

2 more points from Dishman Carbogen Amcis Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Dishman Carbogen Amcis Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising
  • The company holds around INR 1,100 to INR 1,200 crores worth of Requests for Proposals (RFPs) in the India business.
  • They expect to convert approximately 30-35% of these RFPs into firm orders.
  • Physical inspection by a large innovator on a product’s active pharmaceutical ingredient is expected soon, which may translate into additional orders.
  • New contracts and orders are in fluid stages; exact quarters of order fulfillment remain uncertain.
  • For India, the target is to scale up revenue by INR 500 crores over the next 12 to 18 months.

2 more points from Dishman Carbogen Amcis Ltd's call on order book

Create a free account to keep reading this call

Dishman Carbogen Amcis Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Dishman Carbogen Amcis Ltd Q4 FY26 results — key figures

Dishman Carbogen Amcis Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue851716+18.9%720+18.2%
Operating profit (EBITDA)163153+6.5%113+44.2%
Operating margin19%21%-2 pp16%+3 pp
Profit before tax4628+64.3%-10—
Net profit (PAT)2243-48.8%-13—
EPS (₹)1.392.75-49.5%-0.83—

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹507 Cr, net loss ₹67 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Dishman Carbogen Amcis Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Dishman Carbogen Amcis Ltd Q4 FY26 results?

The company targets a consolidated revenue CAGR of approximately 15% over the next 2-3 years, higher than the 10-12% growth achieved previously. Revenue CAGR expected at ~15% over the next 3 years, higher than previous years (Page 28).

What is Dishman Carbogen Amcis Ltd share price analysis?

Dishman Carbogen Amcis Ltd currently shows a below-average growth signal. The stock trades at a P/E of 164.8 with a market cap of ₹2,989 Cr. Investors should review the full earnings analysis for detailed insights.

Is Dishman Carbogen Amcis Ltd planning capital expenditure?

No major CapEx plans currently, except for co-investment with a Japanese innovator, where 100% of CapEx financing is by the partner (Page 18).

Keep Dishman Carbogen Amcis Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.